Latest Period
Q4 2025
Security Snapshot
OCULAR THERAPEUTIX, INC - Common Stock (OCUL) Institutional Ownership
CUSIP: 67576A100
13F Institutional Holders and Ownership History from Q3 2014 to Q1 2026
Institutions Reporting
247
Shares (Excl. Options)
191,554,351
Price
$12.14
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- OCUL on Nasdaq
- Shares outstanding
- 214,467,875
- Price per share
- $8.86
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 191,554,351
- Total reported value
- $2,325,179,443
- % of total 13F portfolios
- 0.02%
- Share change
- +2,393,176
- Value change
- +$30,111,030
- Number of holders
- 247
- Price from insider filings
- $8.86
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- OCUL - OCULAR THERAPEUTIX, INC - Common Stock is tracked under CUSIP 67576A100.
- 247 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 247 to 144 between Q4 2025 and Q1 2026.
- Reported value moved from $2,325,179,443 to $523,535,351.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 247 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 67576A100?
CUSIP 67576A100 identifies OCUL - OCULAR THERAPEUTIX, INC - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67576A100:
Significant Owners of OCULAR THERAPEUTIX, INC - Common Stock (OCUL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +22% | $371,574,057 | +$142,354,542 | 31,785,634 | +62% | FMR LLC | 30 Sep 2025 |
| SUMMER ROAD LLC | 5.7% | $131,657,773 | 12,134,357 | SUMMER ROAD LLC | 04 Dec 2025 | |||
| Deep Track Capital, LP | 5.1% | +20% | $132,787,440 | +$23,640,000 | 11,234,132 | +22% | Deep Track Capital, LP | 05 Feb 2026 |
| BlackRock, Inc. | 5.8% | $118,890,012 | 10,170,232 | BlackRock, Inc. | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | -59% | $81,120,329 | -$71,516,295 | 6,862,972 | -47% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| Opaleye Management Inc. | 2.8% | $34,305,750 | 4,342,500 | Opaleye Management Inc. | 31 Dec 2024 |
As of 31 Dec 2025, 247 institutional investors reported holding 191,554,351 shares of OCULAR THERAPEUTIX, INC - Common Stock (OCUL). This represents 89% of the company’s total 214,467,875 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of OCULAR THERAPEUTIX, INC - Common Stock (OCUL) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 31,785,605 | -0% | 0.02% | $385,877,240 |
| BlackRock, Inc. | 7.3% | 15,602,394 | +48% | 0% | $189,413,062 |
| VANGUARD GROUP INC | 5.4% | 11,575,193 | +26% | 0% | $140,522,844 |
| Summer Road LLC | 5.2% | 11,108,555 | -12% | 98% | $134,857,858 |
| Avoro Capital Advisors LLC | 5% | 10,777,777 | +5.1% | 1.3% | $130,842,213 |
| Deep Track Capital, LP | 3.8% | 8,070,414 | -32% | 2.2% | $97,974,826 |
| VR ADVISER, LLC | 3.4% | 7,315,547 | -44% | 4.4% | $88,810,741 |
| TCG Crossover Management, LLC | 2.7% | 5,740,231 | -6.2% | 2.3% | $69,686,404 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.2% | 4,625,050 | +16% | 0.08% | $56,148,107 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 4,356,547 | +30% | 0% | $52,895,581 |
| ALLIANCEBERNSTEIN L.P. | 2% | 4,341,951 | +27% | 0.02% | $52,711,285 |
| JANUS HENDERSON GROUP PLC | 2% | 4,229,202 | +106% | 0.02% | $51,321,367 |
| STATE STREET CORP | 2% | 4,196,330 | +21% | 0% | $50,943,446 |
| Logos Global Management LP | 1.6% | 3,500,000 | +7.7% | 2.8% | $42,490,000 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 3,207,881 | -17% | 0.03% | $38,943,675 |
| Paradigm Biocapital Advisors LP | 1.4% | 2,935,284 | -16% | 0.95% | $35,634,348 |
| Octagon Capital Advisors LP | 1.2% | 2,623,600 | -0.02% | 4% | $31,850,504 |
| DELTEC ASSET MANAGEMENT LLC | 1.2% | 2,487,934 | -9.9% | 5% | $30,203,519 |
| CITADEL ADVISORS LLC | 1.2% | 2,475,849 | -57% | 0.02% | $30,056,807 |
| Woodline Partners LP | 0.78% | 1,666,136 | +0% | 0.08% | $20,226,891 |
| Opaleye Management Inc. | 0.74% | 1,595,000 | 0% | 2.6% | $19,363,300 |
| GOLDMAN SACHS GROUP INC | 0.72% | 1,547,523 | +94% | 0% | $18,786,930 |
| Saturn V Capital Management LP | 0.7% | 1,504,880 | +31% | 3.4% | $18,269,243 |
| NORTHERN TRUST CORP | 0.68% | 1,462,503 | +24% | 0% | $17,754,786 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.68% | 1,460,457 | +30% | 0% | $17,729,948 |
Institutional Holders of OCULAR THERAPEUTIX, INC - Common Stock (OCUL) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 61,965,588 | $523,535,351 | +$34,442,005 | $8.47 | 144 |
| 2025 Q4 | 191,554,351 | $2,325,179,443 | +$30,111,030 | $12.14 | 247 |
| 2025 Q3 | 188,183,085 | $2,200,137,136 | +$370,394,002 | $11.69 | 214 |
| 2025 Q2 | 156,434,424 | $1,451,692,801 | +$187,013,442 | $9.28 | 182 |
| 2025 Q1 | 137,366,906 | $1,007,015,604 | +$22,122,134 | $7.33 | 195 |
| 2024 Q4 | 133,836,935 | $1,142,923,387 | -$55,464,898 | $8.54 | 177 |
| 2024 Q3 | 139,959,663 | $1,219,693,896 | +$26,591,052 | $8.70 | 167 |
| 2024 Q2 | 137,374,655 | $939,612,942 | +$86,876,988 | $6.84 | 148 |
| 2024 Q1 | 123,359,441 | $1,120,804,208 | +$453,790,279 | $9.10 | 145 |
| 2023 Q4 | 73,706,225 | $328,758,787 | +$150,569,150 | $4.46 | 118 |
| 2023 Q3 | 40,429,130 | $126,952,212 | -$14,507,076 | $3.14 | 112 |
| 2023 Q2 | 43,457,924 | $224,194,712 | +$15,406,633 | $5.16 | 132 |
| 2023 Q1 | 40,293,660 | $212,326,580 | +$6,217,594 | $5.27 | 124 |
| 2022 Q4 | 39,631,821 | $111,363,550 | -$11,852,132 | $2.81 | 110 |
| 2022 Q3 | 42,784,711 | $177,641,770 | -$6,246,780 | $4.15 | 126 |
| 2022 Q2 | 44,283,851 | $178,116,533 | +$2,778,803 | $4.02 | 121 |
| 2022 Q1 | 43,481,638 | $215,332,400 | +$8,618,176 | $4.95 | 127 |
| 2021 Q4 | 41,528,139 | $289,118,916 | -$36,286,646 | $6.97 | 137 |
| 2021 Q3 | 44,501,826 | $445,218,082 | -$45,732,043 | $10.00 | 137 |
| 2021 Q2 | 48,348,304 | $685,490,035 | +$13,999,445 | $14.18 | 146 |
| 2021 Q1 | 47,154,599 | $773,686,821 | -$65,718,337 | $16.41 | 149 |
| 2020 Q4 | 50,434,472 | $1,043,919,487 | +$206,608,703 | $20.70 | 146 |
| 2020 Q3 | 39,773,072 | $302,720,116 | +$7,274,447 | $7.61 | 101 |
| 2020 Q2 | 38,676,765 | $322,007,676 | +$85,260,671 | $8.33 | 103 |
| 2020 Q1 | 28,477,673 | $140,961,353 | +$17,928,044 | $4.95 | 87 |
| 2019 Q4 | 25,199,716 | $99,537,589 | +$4,791,546 | $3.95 | 77 |
| 2019 Q3 | 23,281,316 | $70,779,921 | +$1,143,980 | $3.04 | 73 |
| 2019 Q2 | 22,700,375 | $99,883,931 | +$3,092,692 | $4.40 | 66 |
| 2019 Q1 | 22,319,507 | $88,607,906 | +$2,352,091 | $3.97 | 65 |
| 2018 Q4 | 21,483,102 | $85,497,322 | -$3,739,436 | $3.98 | 66 |
| 2018 Q3 | 21,648,697 | $148,941,295 | -$1,204,780 | $6.88 | 72 |
| 2018 Q2 | 22,017,576 | $148,575,866 | +$9,801,776 | $6.75 | 69 |
| 2018 Q1 | 20,434,189 | $133,026,813 | +$45,596,053 | $6.51 | 63 |
| 2017 Q4 | 13,505,162 | $60,113,388 | -$11,835,912 | $4.45 | 67 |
| 2017 Q3 | 15,581,267 | $96,508,272 | -$1,101,751 | $6.18 | 71 |
| 2017 Q2 | 15,456,517 | $143,279,882 | -$26,251,504 | $9.27 | 71 |
| 2017 Q1 | 18,346,444 | $170,228,516 | +$20,289,375 | $9.28 | 73 |
| 2016 Q4 | 17,394,280 | $145,604,494 | -$10,234,332 | $8.37 | 76 |
| 2016 Q3 | 18,785,162 | $129,054,713 | -$2,936,943 | $6.87 | 70 |
| 2016 Q2 | 19,471,110 | $96,376,641 | -$30,443,305 | $4.95 | 74 |
| 2016 Q1 | 20,860,674 | $201,445,609 | -$1,629,571 | $9.66 | 64 |
| 2015 Q4 | 21,056,974 | $197,303,107 | -$18,088,390 | $9.37 | 71 |
| 2015 Q3 | 20,040,765 | $281,768,540 | +$49,654,282 | $14.06 | 66 |
| 2015 Q2 | 16,138,941 | $339,403,403 | +$93,805,035 | $21.03 | 71 |
| 2015 Q1 | 10,685,998 | $448,639,275 | +$240,805,053 | $41.98 | 56 |
| 2014 Q4 | 5,006,746 | $117,752,025 | +$9,256,090 | $23.52 | 36 |
| 2014 Q3 | 4,629,882 | $69,305,000 | +$69,305,000 | $14.97 | 33 |